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ABSTRACT
Background. Axillary reverse mapping (ARM) is a new
technique developed with the aim of reducing lymphedema
rates by preserving lymphatic drainage of the upper limbs
during sentinel lymph node biopsy and axillary lymph node
dissection (ALND). However, it is unclear whether pres-
ervation of these lymph nodes affects oncological risk. The
present study evaluated the presence of metastases in ARM
nodes.
Methods. A total of 45 patients underwent ARM during
ALND. Blue dye was used for ARM nodes localization. All
axillary lymph nodes, including ARM nodes, were
removed and sent separately for pathological evaluation of
metastases.
Results. ARM identification was achieved in 40/45
patients (88.9 %). The average number of removed ARM
nodes was 1.9. ARM nodes metastasis occurred in 10 of 40
patients (25 %). Patients with an axilla extensively affected
by cancer had an elevated risk of metastasis to the arm’s
lymph nodes (p \ 0.001).
Conclusions. The rate of arm lymph nodes compromised
by metastases calls into question the viability of the ARM
technique. Larger studies may point to particular patient
profiles for which ARM can be safely use.
Sentinel lymph node biopsy (SLNB) is currently the
standard approach to determine breast cancer
dissemination in patients with a clinical node-negative
axilla. A randomized study by the American College of
Surgeons’ Oncology Group, the Z0011 trial,1 recently
showed that axillary lymph node dissection (ALND) can be
omitted in patients with up to two positive sentinel lymph
nodes (SLNs), calling into question how necessary ALND
is in the treatment of breast cancer patients. However, the
Z0011 trial included only patients at a T1 or T2N0M0
clinical stage with up to two positive SLNs treated with
conservative surgery and radiation. ALND continues to be
the standard treatment for patients not fitting the Z0011
trial criteria.2
ALND is associated with a higher rate of postoperative
infection, seroma, lymphedema, paresthesia of the arm/
axilla, and pain3,4 than SLNB alone. Notably, lymphedema
has been reported to occur in 11–30 % of patients and is
generally considered to be the most feared potential com-
plication in these patients.3–7 SLNB has lower morbidity and
lymphedema rates than ALND, although it is clinically sig-
nificant at *8 %.3
The technique of axillary reverse mapping (ARM) was
developed in 2007 with the aim of reducing rates of
lymphedema.8,9 The procedure is based on the hypothesis
that the upper limb’s lymphatic drainage can be distin-
guished from the lymphatic drainage of the breast.
Consequently, identification and preservation of the lym-
phatic arm drainage should result in avoidance of
lymphedema. Initially, the involvement of ARM lymph
nodes was not observed; however, there have since been
reports of metastatic involvement of ARM lymph nodes
and some concordance rate (crossover) between ARM
nodes and the SLN.10–18 Thus, the oncological safety of
this technique has been questioned. The present study was
designed to evaluate the applicability of this technique and
the presence of metastases in ARM nodes.
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Between January 2010 and October 2012, we invited all
women diagnosed with breast cancer and indicated for
ALND (clinically node positive, clinically stage T3 tumors,
and SLN compromised by macrometastases) who were
treated at any of three treatment centers to participate in
this study. The Ethics Committee at the Clinical Hospital
of the Federal University of Parana´ approved the study. A
total of 45 patients signed informed consent forms and
participated in the study.
Procedure
Prior to skin incision, 1–5 ml of blue dye was injected
into the subdermal area of the internal bicipital sulcus of
arm ipsilateral to the breast with cancer. After massaging
the area for 3 min, we proceeded with the standard surgical
procedure planned for the patient. All axillary lymph nodes
and the ARM node(s) were removed and sent separately to
pathology.
Pathological Examination
All nodes were entirely submitted for microscopic
examination. They were cut into 2 mm slices in the lon-
gitudinal plane and when too thin they were submitted as
one piece ‘in toto’. In the sequence they were processed,
they were cut into microscopic slices of 4 lm and stained
with hematoxylin and eosin (H&E). Histological diagnosis
was made taking into account the American Joint Com-
mittee on Cancer (AJCC) Staging Manual, 7th edition.19
Statistical Analyses
Data for the following characteristics were collected for
each patient: age, tumor-node-metastasis (TNM) stage,
histological tumor grade, tumor histology, estrogen recep-
tor (ER) status, HER2/neu hyperexpression, use of
neoadjuvant chemotherapy, type of surgery performed,
pathologic staging of the axilla (TNM), number of upper-
limb lymph nodes identified by ARM, and the presence of
metastases in these lymph nodes. Mean values are reported
with standard deviations (SDs).
A correlational analysis for the occurrence of metastases
in the ARM nodes was conducted in relation to the fol-
lowing variables: age, neoadjuvant chemotherapy use,
primary tumor histologic grade, and the axilla’s pathologic
stage. The v2 test was used to reveal any associations
between the variables. A p value \0.05 was considered
significant.
RESULTS
ARM was performed on a total of 45 female breast
cancer patients (mean age 49.4 years; range 35–85 years).
The clinical characteristics of the patient cohort are sum-
marized in Table 1. Briefly, the vast majority of patients
had stage II or stage III cancer. The histologic grade of
their primary tumors was most commonly grade II,
TABLE 1 Clinical characteristics of the study cohort

























Not otherwise specified 1 2.2
ER status (N = 41)
Positive 22 53.7
Negative 19 46.3







Modified radical mastectomy 40 88.9
Skin-sparing mastectomy 4 8.9
Lumpectomy 1 2.2
ER Estrogen receptor
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followed closely by grade III, with grade I being relatively
rare. Hormonal status was available in 41 of the 45 cases
(91.1 %). Of these, a slight majority of the primary breast
cancer tumors were ER positive. Sixteen patients showed
elevated HER2/neu expression. A large majority of the
patients underwent a modified radical mastectomy,
whereas only a few had a skin-sparing mastectomy, and
only one had a lumpectomy. A majority of the patients
received neoadjuvant chemotherapy (60 %). Upper-limb
lymph nodes were identified through ARM in 40/45
patients (88.9 %). All five patients in whom they could not
be identified received neoadjuvant chemotherapy. The
mean number of ARM nodes removed per patient was 1.9
(SD 1.8) and the mean number of axillary lymph nodes
removed per patient was 15.5 (SD 8.0). 25 % (10/40) of
patients had metastatic involvement of the ARM nodes.
We evaluated the following variables in our analysis of
metastatic ARM nodes: patient age, neoadjuvant chemo-
therapy use, histologic grade of the primary tumor, and
number of lymph nodes in the axilla affected (pN0, pN1,
pN2, and pN3). The resultant data are reported in Table 2.
Briefly, patients with ARM nodes affected, as confirmed by
v2 test, were, on average, significantly younger than
patients without metastasis of ARM nodes. Of the ten cases
with a metastatic upper-limb lymph node, nine were clas-
sified as pN2 or pN3, and one was classified as a pN1.
Therefore, the number of positive axillary nodes was sig-
nificantly associated with the involvement of ARM nodes
(p \ 0.001, v2 test). There was no significant association
between metastatic involvement in ARM nodes and the
histologic grade of the primary tumor (p = 0.342).
Of the 27 patients who received neoadjuvant chemo-
therapy, 7 had an upper-limb lymph node with metastases
(25.9 %), whereas 3 (16.6 %) of the 18 patients who did
not receive neoadjuvant treatment had metastatic ARM
nodes. There was no statistical difference between these
two groups (p = 0.464).
DISCUSSION
Questions remain regarding whether the identification
rate for ARM nodes is satisfactory, whether the technique
is safe, and whether preservation of ARM nodes reduces
rates of lymphedema. The identification rate for arm-
draining lymph nodes obtained in the present study
(88.8 %) indicates that the ARM technique was effective
in the great majority of patients and is in the upper range
of rates reported in the literature (61.0–90.3 %) for ARM
with patent blue dye8–18,20 (Table 3). Gennaro et al.22
injected an isotope on the back of the ipsilateral hand and
were able to identify arm-draining lymph nodes in 45 of
60 patients (75 %). In a pilot study reported in 2009,
Noguchi23 described a new technique in which they used
a fluorescence imaging system with the injection of in-
docyanine green and were able to identify arm-draining
lymph nodes in seven of eight patients. In a subsequent
larger study published in 2012, Noguchi et al.24 achieved
an identification rate of 85 % (29/34 patients) with this
technique.
The standard technique for identification of the SLN is
the combined use of blue dye and isotope (technetium-
99m). So far, only two authors used a combined technique
to identify ARM nodes. In the study of Nos et al.,21 all
patients underwent isotope injection in the ipsilateral hand
the day before surgery, and they also had blue dye injection
during anesthesia. These authors achieved an identification
rate of 91 %. Tausch et al.26 performed ARM in 143
patients: 74 patients were injected with blue dye only; 8
patients were injected with radioactive only; and in 61
patients, a combination of blue dye and radioisotope was
injected. The overall identification rate was 78 %: 62 % for
blue dye only, 100 % for radioisotope only, and 95 % for
the combined technique.
As summarized in Table 4, some authors have investi-
gated whether the ARM technique can be applied during
SLNB; in these cases, they obtained considerably lower
identification rates for upper-limb lymph nodes
(37.5–47.0 %) and sometimes considered the procedure
insufficient.10,11,14,15,17,18,20,23 This difficulty arises mainly
because of the location of the arm’s lymph node, which in
most cases is situated below or at the level of the second
intercostobrachial nerve, making it difficult to identify
during SLNB.
TABLE 2 Factors associated with metastasis-positive ARM nodes
Factor No. of cases ARM nodes p value
Positive Negative
Mean age, years (%) 44.1 52.2 0.015
Neoadjuvant chemotherapy [n (%)]
Yes 22 7 (31.8) 15 (68.2) NS
No 18 3 (16.7) 15 (83.3)
Histologic grade [n (%)]
1 6 2 (33.3) 4 (66.7)
2 20 3 (15.0) 17 (85.0) NS
3 14 5 (35.7) 9 (64.3)
Axillary stage (pN, TNM) [n (%)]
pN0 23 0 (0.0) 23 (100.0)
pN1 6 1 (16.7) 5 (83.3)
pN2 or pN3 11 9 (81.8) 2 (18.2) \0.001
The five patients in whom ARM nodes could not be identified were
excluded from these analyses
ARM Axillary reverse mapping, NS not significant
Axillary Reverse Mapping in Breast Cancer 2199
The authors of the first studies published did not find
metastases in the lymph nodes draining the arm, even in
patients with an extensive nodal involvement.8,9,17 However,
each of these studies included analyses of only a small
number of ARM nodes. Thompson et al.8 performed the
ARM procedure on 40 patients with an indication for SLNB
with or without ALND; however, they sent only seven ARM
nodes for pathological analysis. Similarly, Nos et al.9
included 21 patients indicated for ALND and managed to
evaluate the ARM node in only ten cases. Boneti et al.17
performed ARM on 131 patients receiving SLNB, but only
analyzed 12 ARM lymph nodes. Subsequently, Nos et al.21
were able to analyze nodes recovered from 21/23 patients
indicated for ALND. Of the 21 recovered specimens, three
had metastases (14 %). All three cases had an extensive
compromised axilla (pN3a). More recently, other authors
have found metastases in 8.7–25 % of ARM
nodes.8–14,18,21,24–26 Since the series reported on thus far are
small, it remains unclear how frequent ARM node involve-
ment is and what the profile of at-risk patients might be.27
There are few studies that reported how the pathological
examination of the ARM nodes was done. Gobardhan
et al.28 examined the nodes after staining with H&E and
immunohistochemically (IHC). As we did in our study,
other authors8,13,15,17,18,24,25 analyzed the ARM nodes after
staining with H&E. It is generally accepted that IHC are
TABLE 3 Results of ARM during the ALND procedure









Thompson et al.8 No 18 61.0 % 0.0 % 0.0 % (0/7) Blue dye
Nos et al.9 No 21 71.0 % NR 0.0 % (0/10) Blue dye
Nos et al.21 No 23 91.0 % NR 14 % (3/21) Blue dye and isotope
Casabona et al.11 Yes 9 88.9 % 0.0 % 0.0 % (0/3) Blue dye
Kang et al.10 Yes 129 78.3 % 18.9 % 9 % (9/101) Blue dye
Ponzone et al.12 No 49 73.5 % NR 11 % (3/27) Blue dye
Boneti et al.17 Yes 47 40.6 % 2.8 % 0.0 % (0/15) Blue dye
Bedrosian et al.13 No 30 70.0 % NR 13 % (2/15) Blue dye
Deng et al.14 Yes 69 NR 8.7 % 8.7 % (6/69) Blue dye
Rubio et al.25 No 36 83.3 % 14.0 % 13 % (4/30) Blue dye
Gobardhan et al.28 No 93 90.3 % NR 12 % (11/93) Blue dye
Han et al.15 Yes 97 NR 7.2 % 12 % (2/17) Blue dye
Noguchi et al.24 Yes 34 85.0 % 28.0 % 25 % (11/29) Fluorescent
Tausch et al.26 No 143 78.0 % NR 15 % (17/115) Blue dye and isotope
Connor et al.20 Yes 57 72.0 % 10.0 % 15.7 % (3/19) Blue dye
Gennaro et al.22 No 60 75.0 % NR No data Isotope
Schunemann et al. (2014) No 45 88.9 % NR 25 % (10/45) Blue dye
ARM Axillary reverse mapping, SLNB sentinel lymph node biopsy, NR not reported
TABLE 4 Summary of the literature results of ARM during SLNB










Boneti et al.17 131 42.7 % 3.9 0.0 % (0/12) Blue dye
Casabona
et al.11
72 37.5 % 0.0 0.0 % (0/3) Blue dye
Kang et al.10 129 NR 18.9 8.3 % (8/96) Blue dye
Boneti et al.17 220 40.6 % 2.8 0.0 % (0/15) Blue dye
Deng et al.14 69 NR 8.7 8.7 % (6/69) Blue dye
Han et al.15 14 NR 7.2 0.0 % (0/4) Blue dye
Noguchi et al.24 97 43.0 % 28.0 11.9 % (5/42) Fluorescent
Connor et al.20 155 47.0 % 12.0 0.0 % (0/18) Blue dye
ARM Axillary reverse mapping, SLNB sentinel lymph node biopsy, NR not reported
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more sensitive for picking up micrometastasis compered
with conventional H&E. However, we will probably not
need to remove the ARM nodes with micrometastasis as
we already do with the SLN with micrometastasis.
There are two possible explanations for metastatic
involvement of arm-draining lymph nodes.27 First, it could
be a consequence of the natural progression of the disease.
There are lymphatic interconnections in the axilla between
the arm and SNL draining from the breast. Breast cancer
progression may alter the pattern of lymphatic flow,
allowing the upper limb’s lymph nodes to be compromised.
Second, it could be a result of the arm-draining lymph
nodes being situated in the central group, which is too close
to the breast’s lymphatic drainage to be preserved.
Special attention should be paid to convergence between
the SLN and ARM nodes, which makes it impossible to
preserve the arm-draining lymph nodes. Such convergence
has been reported to occur in as little as 2.8 % and as much
as 28 % of cases.10,11,14,15,17,18,20,23 In studies by Deng
et al.14 and Noguchi,23 the ARM nodes with metastasis
were the same as the SLN, showing that convergence is an
important contributing factor to metastases in the lymph
nodes of the upper limbs.14 However, in a study published
by Rubio et al.,25 4 of 30 patients (13 %) had metastases in
ARM nodes, and none of the metastatic nodes corre-
sponded with the SLN.
Our study did not evaluate convergence since all of our
patients underwent ALND straightaway. Our rate of
metastasis in the arm’s lymph nodes was higher than that
found by Kang et al.10 (9 %), Deng et al.14 (8.7 %), and
Han et al.15 (12 %). In these prior studies, the patient
cohorts had a clinically negative axilla and therefore an
indication for SLNB. They were early-stage patients with a
low chance of axillary and ARM node involvement. We
know that 40–60 % of patients with a positive SNLB
finding do not have involvement of axillary lymph nodes
beyond the SLN.1–3 Therefore, the rate of metastases in
ARM nodes (25 %) in the present study is close to that of
other studies in which only patients who already had an
indication for ALND were included, such as the studies by
Noguchi et al.24 (25 %) and Nos et al.21 (14 %).
Corroborating other previously published stud-
ies,12,20,21,25 our results show an association between the
number of lymph nodes involved in the axilla and the pre-
sence of metastases in ARM nodes; patients with extensive
involvement of cancer in the axilla are at greater risk of
metastasis to the lymph nodes of the upper limbs. Thus, such
patients should not be candidates for the ARM technique.
There are few studies that included patients who
received neoadjuvant chemotherapy.9,13,21,24,25,28 Only our
study and that of Gobardhan et al.28 evaluated the differ-
ence between the group receiving neoadjuvant
chemotherapy versus a group that did not, and neither
found a significant group difference for the incidence of
metastasis in ARM nodes. Recently, studies have evaluated
SLNB after neoadjuvant therapy in patients with an ini-
tially positive axilla.29–31 Both the ACOSOG Z1071
clinical study30 and the SENTINA study31 obtained higher-
than-expected false negative rates (12.6 and 14.2 %,
respectively). It would be premature to change standard
clinical practices now. However, in the future, some
patients with an initially positive axilla may be spared
ALND if the SLNB technique can be proven reliable and
oncologically safe after neoadjuvant chemotherapy.
The ARM technique was developed to preserve the
arm’s lymph nodes during ALND and, consequently, to
prevent lymphedema. However, very few studies have
evaluated this outcome.15,22,26 Using ARM, Tausch et al.26
were able to preserve one or more upper-limb lymph nodes
in 71/143 cases. After a median follow-up of 19 months, 35
of 114 patients developed lymphedema, and the ARM
procedure was not associated with a significant reduction in
morbidity. At the univariate analysis, obesity was the only
risk factor for lymphedema. Gennaro et al.22 performed
ARM on 60 patients, including 45 patients (group A) who
underwent selective ALND wherein ARM nodes were
preserved, and 15 patients (group B) who received standard
ALND with removal of the arm’s lymph nodes. The two
groups were similar in terms of risk factors for lymphe-
dema. After monitoring for an average of 16 months, four
patients in group A developed lymphedema (9 %) versus
five patients in group B (33 %; p = 0.035). The number of
patients in both of these studies22,26 was relatively small, as
was the period of follow-up, which could lead to certain
biases. Approximately 25 % of patients develop lymphe-
dema more than 3 years after surgery.5 Thus, studies that
monitor patients for less than 5 years are prone to under-
estimate the overall prevalence of lymphedema.5
Klompenhouwer et al.32 are currently carrying out a con-
trolled, randomized study designed to investigate ARM’s
ability to reduce the risk of lymphedema.
CONCLUSIONS
Like other studies published to date, our study evaluated
a small number of patients. However, the finding that 25 %
of the ARM nodes had metastatic involvement is note-
worthy. At this rate, it is oncologically unacceptable to
preserve metastatic lymph nodes in the arm or those that
coincide with the SLN during SLNB, which calls into
question ARM’s viability and safety. Studies with a higher
number of patients may be able to demonstrate whether
there is a certain patient profile for which this technique
could be applied safely.
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